UY27816A1 - Nueva combinacion - Google Patents
Nueva combinacionInfo
- Publication number
- UY27816A1 UY27816A1 UY27816A UY27816A UY27816A1 UY 27816 A1 UY27816 A1 UY 27816A1 UY 27816 A UY27816 A UY 27816A UY 27816 A UY27816 A UY 27816A UY 27816 A1 UY27816 A1 UY 27816A1
- Authority
- UY
- Uruguay
- Prior art keywords
- new combination
- inhibitor
- pde5
- cgmp
- ace
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0211919A GB0211919D0 (en) | 2002-05-23 | 2002-05-23 | Novel combination |
GB0229784A GB0229784D0 (en) | 2002-12-20 | 2002-12-20 | Novel combination |
Publications (1)
Publication Number | Publication Date |
---|---|
UY27816A1 true UY27816A1 (es) | 2003-12-31 |
Family
ID=29585817
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY27816A UY27816A1 (es) | 2002-05-23 | 2003-05-21 | Nueva combinacion |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP1506015A2 (pt) |
JP (1) | JP2005529927A (pt) |
KR (1) | KR20050004195A (pt) |
CN (1) | CN1655820A (pt) |
AR (1) | AR040090A1 (pt) |
AU (1) | AU2003223071A1 (pt) |
BR (1) | BR0311191A (pt) |
CA (1) | CA2485984A1 (pt) |
IL (1) | IL164975A0 (pt) |
MX (1) | MXPA04010951A (pt) |
NO (1) | NO20045517L (pt) |
PA (1) | PA8574201A1 (pt) |
PE (1) | PE20040514A1 (pt) |
PL (1) | PL374198A1 (pt) |
RU (1) | RU2004133973A (pt) |
TW (1) | TW200407153A (pt) |
UY (1) | UY27816A1 (pt) |
WO (1) | WO2003099194A2 (pt) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7019010B2 (en) | 2001-09-27 | 2006-03-28 | Novertis Ag | Combinations |
GB0318094D0 (en) * | 2003-08-01 | 2003-09-03 | Pfizer Ltd | Novel combination |
DE102004011512B4 (de) | 2004-03-08 | 2022-01-13 | Boehringer Ingelheim Vetmedica Gmbh | Pharmazeutische Zubereitung enthaltend Pimobendan |
EP1579862A1 (en) * | 2004-03-25 | 2005-09-28 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure |
US8980894B2 (en) | 2004-03-25 | 2015-03-17 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure |
FR2902009B1 (fr) * | 2006-06-13 | 2012-12-07 | Bioprojet Soc Civ | Utilisation d'un inhibiteur de vasopeptidase pour le traitement de l'hypertension arterielle pulmonaire |
AU2007287024A1 (en) | 2006-08-24 | 2008-02-28 | Surface Logix, Inc. | Pharmacokinetically improved compounds |
EP1920785A1 (en) | 2006-11-07 | 2008-05-14 | Boehringer Ingelheim Vetmedica Gmbh | Liquid preparation comprising a complex of pimobendan and cyclodextrin |
EP2825159B1 (en) | 2012-03-15 | 2022-06-22 | Boehringer Ingelheim Vetmedica GmbH | Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof |
WO2015007760A1 (en) | 2013-07-19 | 2015-01-22 | Boehringer Ingelheim Vetmedica Gmbh | Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition |
EP3106150B1 (en) | 2013-12-04 | 2021-07-28 | Boehringer Ingelheim Vetmedica GmbH | Improved pharmaceutical compositions of pimobendan |
US10537570B2 (en) | 2016-04-06 | 2020-01-21 | Boehringer Ingelheim Vetmedica Gmbh | Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4316906A (en) * | 1978-08-11 | 1982-02-23 | E. R. Squibb & Sons, Inc. | Mercaptoacyl derivatives of substituted prolines |
GB9013750D0 (en) * | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
GB9401090D0 (en) * | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
US6143746A (en) * | 1994-01-21 | 2000-11-07 | Icos Corporation | Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use |
PT1049695E (pt) * | 1997-11-12 | 2002-07-31 | Bayer Ag | Imidazotriazinonas 2-fenil substituidas enquanto inibidores de fosfodiesterase |
TWI265925B (en) * | 1999-10-11 | 2006-11-11 | Pfizer | Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them |
NZ517324A (en) * | 1999-10-11 | 2003-09-26 | Pfizer | 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-YL)- dihydropyrazolo[4,3-d]pyrimidin-7-ones as phosphodiesterase inhibitors |
-
2003
- 2003-05-09 CA CA002485984A patent/CA2485984A1/en not_active Abandoned
- 2003-05-09 CN CNA038118262A patent/CN1655820A/zh active Pending
- 2003-05-09 PL PL03374198A patent/PL374198A1/xx not_active Application Discontinuation
- 2003-05-09 BR BR0311191-1A patent/BR0311191A/pt not_active IP Right Cessation
- 2003-05-09 EP EP03719042A patent/EP1506015A2/en not_active Withdrawn
- 2003-05-09 MX MXPA04010951A patent/MXPA04010951A/es unknown
- 2003-05-09 KR KR10-2004-7018868A patent/KR20050004195A/ko active IP Right Grant
- 2003-05-09 WO PCT/IB2003/001889 patent/WO2003099194A2/en not_active Application Discontinuation
- 2003-05-09 JP JP2004506721A patent/JP2005529927A/ja not_active Abandoned
- 2003-05-09 AU AU2003223071A patent/AU2003223071A1/en not_active Abandoned
- 2003-05-09 RU RU2004133973/15A patent/RU2004133973A/ru not_active Application Discontinuation
- 2003-05-12 TW TW092112826A patent/TW200407153A/zh unknown
- 2003-05-19 PE PE2003000482A patent/PE20040514A1/es not_active Application Discontinuation
- 2003-05-21 UY UY27816A patent/UY27816A1/es not_active Application Discontinuation
- 2003-05-21 AR ARP030101762A patent/AR040090A1/es unknown
- 2003-05-22 PA PA20038574201A patent/PA8574201A1/es unknown
-
2004
- 2004-11-01 IL IL16497504A patent/IL164975A0/xx unknown
- 2004-12-17 NO NO20045517A patent/NO20045517L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AR040090A1 (es) | 2005-03-16 |
PA8574201A1 (es) | 2003-12-19 |
TW200407153A (en) | 2004-05-16 |
BR0311191A (pt) | 2005-03-01 |
KR20050004195A (ko) | 2005-01-12 |
CA2485984A1 (en) | 2003-12-04 |
AU2003223071A1 (en) | 2003-12-12 |
IL164975A0 (en) | 2005-12-18 |
JP2005529927A (ja) | 2005-10-06 |
PE20040514A1 (es) | 2004-08-24 |
MXPA04010951A (es) | 2005-06-08 |
EP1506015A2 (en) | 2005-02-16 |
WO2003099194A3 (en) | 2004-06-03 |
CN1655820A (zh) | 2005-08-17 |
PL374198A1 (en) | 2005-10-03 |
RU2004133973A (ru) | 2005-09-10 |
WO2003099194A2 (en) | 2003-12-04 |
NO20045517L (no) | 2004-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1105390T1 (el) | Θepαπευτικη αγωγη της πνευμονικης υπερτασης | |
UY27816A1 (es) | Nueva combinacion | |
ECSP056173A (es) | Composicion que comprende un inhibidor de pde4 y un inhibidor de pde5 | |
ECSP034519A (es) | Inhibidores de xantina fosfodiesterasa v | |
DK1371647T3 (da) | Pyrazolopyrimidinon-cGMP PDE5-inhibitorer til behandling af sexualforstyrrelse | |
DK1440709T3 (da) | Kombinationer, der omfatter cGMP PDE5 inhibitorer | |
IS6689A (is) | Forlyf af fosfónat-kirna hliðstæðum og aðferð tilað velja og búa þær til | |
NO20050400L (no) | Nytt kombinasjonspreparat | |
NO20001583D0 (no) | Stimulering av hematopoetiske celler in vitro | |
DK1268480T3 (da) | 8-Quinolinxanthin- og 8-isoquinolinxanthinderivater som PDE5-inhibitorer | |
DE60134692D1 (de) | Beleuchtungsanordnung für Tastaturen und die dynamische bzw. individuelle Beleuchtung der Tasten sowie Verfahren zu ihrer Verwendung | |
BR9710570A (pt) | Inibidor de adesão de células | |
NO20054369L (no) | Anvendelse av en IBAT-inhibitor for behandling og profylakse av forstoppelse | |
ATE234091T1 (de) | Thrombin inhibitoren | |
BR0314196A (pt) | Inibidores de tgf-beta | |
GT200300231A (es) | Inhibidores de hiv-integrasa, composiciones farmaceuticas y metodos para su uso | |
MXPA05006368A (es) | Inhibidores aminocianopiridina de proteina cinasa-2 activada por proteina cinasa activada por mitogeno. | |
DK1285065T3 (da) | Konstruerede proteiner, der fluorescerer ved lange bölgelængder | |
DOP2003000645A (es) | Nueva combinacion | |
ATE302781T1 (de) | Sulfamidothienopyrimidine zur verwendung als phosphodiesterase v-hemmer | |
PA8477601A1 (es) | Inhibidores de las fkbp | |
ATE335824T1 (de) | Isolierte luziferasen sowie deren verwendung | |
DE60136573D1 (de) | Gewebefixativzusammensetzung | |
NO20065850L (no) | Fremgangsmate for identifisering av PDE5-modulatorer | |
DOP2003000649A (es) | Nueva combinacion |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20150520 |